Sponsors with generic products that have been stripped of their bioequivalence ratings because of data integrity problems at two contract research organizations may want regulatory flexibility from the US Food and Drug Administration, but generally appear to have only two choices.
FDA officials have said repeatedly that sponsors can talk with them about options, but for the most part the choices...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?